A Prophylactic HIV Vaccine Trial to Evaluate the Safety and Immunogenicity of HIV Clade C DREP Alone and in Combination With a Clade C ENV Protein in Healthy HIV-uninfected Adults

NCT04844775 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

68

Enrollment

OTHER_GOV

Sponsor class

Conditions

Healthy Adults

Interventions

BIOLOGICAL: Drep-HIV-PT1 0.2mg and CN54gp140/MPLA-L
BIOLOGICAL: DREP-HIV-PT1 1mg and CN54gp140/MPLA-L (see above)
BIOLOGICAL: DNA-HIV-PT123 4mg and CN54gp140/MPLA-L

Sponsor

ANRS, Emerging Infectious Diseases

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]